Tralokinumab Disease Interactions
There are 3 disease interactions with tralokinumab.
Tralokinumab (applies to tralokinumab) live vaccines
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Vaccination
Tralokinumab may alter patient immunity and increase risk of infection after administration of live vaccines. Before starting this drug, complete all age-appropriate vaccinations according to current guidelines. Do not use live vaccines in patients treated tralokinumab.
Tralokinumab (applies to tralokinumab) parasitic infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Tralokinumab may influence the immune response against helminth infections by inhibiting interleukin 13 (IL-13) signaling. Patients with preexisting helminth infections should be treated before initiating treatment with this drug. If patients become infected while already in treatment and do not respond to antihelminth treatment, discontinue this drug until infection resolves.
Tralokinumab (applies to tralokinumab) visual disturbances
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance
Conjunctivitis and keratitis occurred more frequently in patients with atopic dermatitis who received tralokinmab, being conjunctivitis the most frequently reported eye disorder. Patients should report new onset or worsening of any existing eye symptoms to their healthcare provider.
Switch to professional interaction data
Tralokinumab drug interactions
There are 24 drug interactions with tralokinumab.
Report options
More about tralokinumab
- tralokinumab consumer information
- Check interactions
- Compare alternatives
- Reviews (8)
- Side effects
- Dosage information
- During pregnancy
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opzelura
Opzelura is used to treat atopic dermatitis (eczema) and nonsegmental vitiligo. It is a topical ...
Eucrisa
Eucrisa (crisaborole) is used to treat mild to moderate eczema (atopic dermatitis) Includes Eucrisa ...
Adbry
Adbry is used to treat moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 ...
Cibinqo
Cibinqo (abrocitinib) tablets are used for the treatment of moderate to severe eczema (atopic ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Temovate
Temovate is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen ...
Lidex
Lidex is used for atopic dermatitis, dermatitis, eczema, psoriasis
Clobex
Clobex is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen planus ...
Olux
Olux is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen planus ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
